Industry observation: As domestic innovation and R&D continue to heat up, the flow of talents in multinational pharmaceutical companies is increasing

In recent years, the pharmaceutical industry has accelerated its transformation and upgrading in the direction of innovation under the implementation of medical reform policies such as speeding up the review of new drugs, normalization of centralized procurement, medical insurance negotiations, and consistency evaluation
.
At present, the domestic enthusiasm for innovative drug research and development is high, and the superimposed capital continues to increase.
The industry generally believes that China has ushered in a new era of innovative drugs
.
However, as the domestic pharmaceutical innovation and R&D continue to heat up, the industry's talent flow has been turbulent, and the flow of talents in multinational pharmaceutical companies is intensifying
.
As innovation and R&D continue to heat up, the flow of talents in multinational pharmaceutical companies is intensifying (Image source: Pharmaceutical Network) The author understands from public information that AstraZeneca has left mid-level and high-level talents particularly frequently this year, and most of these people's destinations after leaving are local Innovative medicine company
.
For example, in mid-November, it was reported that Du Haochen, former vice president of AstraZeneca China and head of the county business department, officially joined BeiGene as the head of the broad market; on September 22, AstraZeneca's former Eastern RGM and sales consultant committee Chairman Zhang Anwei resigned and joined Luoxin Group as the general manager of the company's innovative drug direct sales business and group vice president; on August 3, Dong Lijun, the former general manager of AstraZeneca China's digestion and full product development business department, was also announced, He will serve as Luo Xin's deputy general manager, as well as the company's executive vice president and chief operating officer (COO)
.
The financial report for the third quarter of 2021 shows that AstraZeneca's performance in China in the third quarter was US$1.
49 billion, accounting for 15% of the total global revenue, which was down from 20% in the first half of this year
.
The reason behind this is related to the decline in sales of osimertinib in China
.
AstraZeneca further pointed out in the report that since the landing of the new version of the medical insurance catalog in March this year, the number of patients covered by osimertinib has not offset the impact of medical insurance price cuts
.
In the third quarter, sales of osimertinib in the Chinese market fell by 10%
.
In addition to AstraZeneca, in the first half of 2021, the news about the former president of Merck & Co.
China Luo Wanli or joining a Chinese innovative pharmaceutical company also attracted great attention in the industry
.
In July this year, the biopharmaceutical company "Jixing Pharmaceutical" officially announced the appointment of Mr.
Luo Wanli as the company’s chief executive officer and member of the board of directors, effective immediately
.
It is reported that after taking office, Mr.
Luo Wanli will be responsible for the development of Etripamil, a licensed drug for the treatment of paroxysmal supraventricular tachycardia (PSVT) and other cardiovascular disease indications announced by Ji Xing in Greater China
.
For another example, in late July this year, Medicilon announced the appointment of Dr.
Xuedong Dai as Executive Vice President of Medicilon International R&D Services
.
It is reported that before joining Medicilon, Dai Xuedong served as an executive in Xi'an Janssen, Huiyuan Biotechnology, GSK, Xenoport and other large domestic and foreign pharmaceutical companies and CROs
.
According to the analysis, the business performance in China, including multinational pharmaceutical companies such as AstraZeneca, has been relatively eye-catching in the past.
In the process of business adjustment, the accompanying executive changes have also become the norm
.
From the perspective of the whereabouts of middle-level and high-level talents in these multinational pharmaceutical companies, local innovative drug companies seem to be more and more popular and become a new "home" for many middle-level and high-level talents.
This also illustrates the momentum of domestic innovative drugs from the side.
, And the industry is optimistic about the future development of the local innovative drug industry
.
It is worth mentioning that senior executives of foreign companies joining local companies may also become "unaccustomed"
.
For example, on November 3 this year, Junshi Biotech announced that Chief Commercial Officer Qian Wei has recently resigned from the company due to personal development reasons, and the last working day is November 12, 2021
.
And from Qian Wei joined Junshi Bio, only 4 months time, this resignation news also attracted the attention of the industry
.
Some analysts believe that due to the relatively conservative scale of Junshi’s sales team, the sales performance in 2019 has widened the gap with Cinda Bio, and the gap has further widened in the following two years
.
It is understood that the chief commercial officer of a local pharmaceutical company is different from the subdivision and systematization of a multinational pharmaceutical company.
It needs to be fully responsible for the management of the sales team, strategic marketing department, marketing department, oncology product medical affairs department, sales training department, etc.
, The pressure can be imagined
.
At present, the battle for talents between local pharmaceutical companies and multinational companies has intensified.
From the perspective of the industry, under the background of domestic innovative drug research and development, it is undoubtedly a good phenomenon for multinational pharmaceutical companies to join local pharmaceutical companies, but compared with multinational pharmaceutical companies , Local pharmaceutical companies also need to work harder on market strategies and build a more detailed internal structure to allow the influx of talents to concentrate on "big things
.
"